[Alternative therapy concept for the treatment of psychosomatic disorders. Controlled double-blind evaluation of fluspirilene versus bromazepam].
Today, Fluspirilene 1.5 mg i.m. (Imap 1,5 mg), is used to treat psychosomatic conditions, anxiety states and psychogenic disorders. The present article reports on clinical studies involving these indications. The efficacy of Fluspirilene 1.5 mg i.m. was demonstrated in patients with functional organic complaints, autonomic emotional symptom complexes, patients with anxiety, patients with functional heart complaints, and patients with functional gynaecological disorders. The results of a controlled study of 1.5 mg Fluspirilene i.m. and 6 mg Bromazepam are discussed. Forty-five patients from a neurologist's practice participated, all of whom had been classified as treatment-requiring patients with neurotic anxiety, on the basis of the physician's diagnosis and psychometric examination. Treatment lasted 42 days. The clinical assessment by the physician revealed that 1.5 mg Fluspirilene i.m. is significantly more effective than Bromazepam. The psychometric findings showed that patients with marked somatic anxiety treated with Fluspirilene showed greater improvement as expressed in a reduction in anxiety, lightening of mood, and increased activity, as compared with Bromazepam.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001960:Bromazepam / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005484:Fluspirilene / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011594:Psychometrics; D011602:Psychophysiologic Disorders / Q000188:drug therapy* / Q000523:psychology; D013141:Spiro Compounds / Q000627:therapeutic use*
D014151:Anti-Anxiety Agents; D013141:Spiro Compounds; D005484:Fluspirilene; D001960:Bromazepam
Alternatives Therapiekonzept zur Behandlung psychosomatischer Beschwerden. Kontrollierte Doppelblind-Prüfung von Fluspirilen versus Bromazepam.